Impact of a Nurse Navigator on Genomic Testing and Timely Treatment Decision Making in Patients With Breast Cancer

Kelly A. McAllister, RN, BSN, OCN®, CBCN®, and Mary L. Schmitt, MS, APRN, FNP-BC, AOCNP®

The purpose of this quality improvement project was to define best practices for identifying appropriate patients for genomic testing and improve timeliness for ordering tests and reporting results. An interdisciplinary team of surgeons, radiologists, medical oncologists, and nurses agreed that the RN navigator would be the key person to facilitate timely access to genomic profiling.

At a Glance
• Genomic profiling has become the standard of care for patients with early-stage breast cancer to assist in developing individualized treatment plans.
• Nurse navigators can play a key role in improving timeliness of care.
• The APN-RN model led to improvements in turnaround time and compliance with the National Comprehensive Cancer Network’s recommendations for genomic testing.

It is important to note that the role of the navigator can be that of an RN or an APN.

Literature Review

Breast cancer mortality has declined in the past 20 years. Rapid advancements in technology, molecular biology, and genetics have had a great impact on diagnosis and treatment and individualized treatment plans are on the rise (National Cancer Institute, 2015). Attention is now focused on who should not receive chemotherapy rather than who should receive it. Tumors of the same histologic type may have individual mutations with different treatment responses. Tumor profiling is the evaluation of genomic expression, which is useful in identifying a cancer diagnosis, prognosis, and therapeutics (Dacic, 2011). Oncotype DX provides quantitative assessment of chemotherapy benefit and risk of distant recurrence, which increases confidence in creating individualized treatment plans (Genomic Health, 2015). The Oncotype DX assay gene panel and recurrence score were validated in the National Surgical Adjuvant Breast and Bowel Project B-14, demonstrating that the recurrence score can be used as an accurate estimate of the risk of distant recurrence and overall survival in individual patients (Paik et al., 2004).

The National Comprehensive Cancer Network (NCCN, 2015) suggests the use of genomic profiling to further refine risks and benefits for adjuvant chemotherapy for women with early-stage ER+, HER2/neu-negative tumors measuring greater than 0.5 cm.

APN-RN Nurse Navigators

The nurse navigator is a key member of an interdisciplinary team (Freeman &...